Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab as add-on to Botox in migraine
NCT05492695Phase 4Terminated
- Sponsor
- Diamond Headache Clinic
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of galcanezumab in migraine, sponsored by Diamond Headache Clinic. Started Oct 2022; status: terminated.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05492695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492695.